BR112017025728A2 - fragmentos mutantes da proteína ras - Google Patents
fragmentos mutantes da proteína rasInfo
- Publication number
- BR112017025728A2 BR112017025728A2 BR112017025728A BR112017025728A BR112017025728A2 BR 112017025728 A2 BR112017025728 A2 BR 112017025728A2 BR 112017025728 A BR112017025728 A BR 112017025728A BR 112017025728 A BR112017025728 A BR 112017025728A BR 112017025728 A2 BR112017025728 A2 BR 112017025728A2
- Authority
- BR
- Brazil
- Prior art keywords
- ras protein
- amino acid
- region
- peptide
- mutant fragments
- Prior art date
Links
- 102000016914 ras Proteins Human genes 0.000 title abstract 5
- 108010014186 ras Proteins Proteins 0.000 title abstract 5
- 239000012634 fragment Substances 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 125000000539 amino acid group Chemical group 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 230000035772 mutation Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001164—GTPases, e.g. Ras or Rho
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
- C12Y306/05—Hydrolases acting on acid anhydrides (3.6) acting on GTP; involved in cellular and subcellular movement (3.6.5)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Mycology (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
a presente invenção revela um peptídeo adequado para induzir uma resposta imune. o peptídeo corresponde a um fragmento da proteína ras e compreende uma região de 8 aminoácidos que inclui uma posição mutada da proteína ras. a referida região possui pelo menos 6 resíduos de aminoácidos, que não a posição mutada, que são idênticos à região correspondente da proteína ras. o peptídeo tem mutação pontual no aminoácido correspondente à posição mutada e a posição mutada é a posição 146 ou 117 da proteína ras.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15172418 | 2015-06-16 | ||
| PCT/EP2016/063920 WO2016202937A1 (en) | 2015-06-16 | 2016-06-16 | Mutated fragments of the ras protein |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112017025728A2 true BR112017025728A2 (pt) | 2018-08-07 |
Family
ID=53404437
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112017025728A BR112017025728A2 (pt) | 2015-06-16 | 2016-06-16 | fragmentos mutantes da proteína ras |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20190374628A1 (pt) |
| EP (1) | EP3310808A1 (pt) |
| JP (1) | JP2018518177A (pt) |
| KR (1) | KR20180021072A (pt) |
| CN (1) | CN107922472A (pt) |
| AU (1) | AU2016280770A1 (pt) |
| BR (1) | BR112017025728A2 (pt) |
| CA (1) | CA2989373A1 (pt) |
| CL (1) | CL2017003228A1 (pt) |
| HK (1) | HK1248714A1 (pt) |
| IL (1) | IL256077A (pt) |
| MX (1) | MX2017015927A (pt) |
| RU (1) | RU2018101225A (pt) |
| WO (1) | WO2016202937A1 (pt) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3051252A1 (en) | 2017-02-01 | 2018-08-09 | Modernatx, Inc. | Immunomodulatory therapeutic mrna compositions encoding activating oncogene mutation peptides |
| CN110709094A (zh) * | 2017-02-03 | 2020-01-17 | 威斯康星州医药大学股份有限公司 | Kras肽疫苗组合物及其使用方法 |
| WO2020002650A1 (en) | 2018-06-29 | 2020-01-02 | Targovax Asa | A formulation |
| CA3109496A1 (en) * | 2018-08-22 | 2020-02-27 | Fred Hutchinson Cancer Research Center | Immunotherapy targeting kras or her2 antigens |
| CN110172480B (zh) * | 2019-06-11 | 2020-01-07 | 北京鼎成肽源生物技术有限公司 | 双抗原表位融合基因重组慢病毒载体、抗原提呈细胞和ctl细胞及其构建方法和应用 |
| CN110205298B (zh) * | 2019-06-11 | 2020-05-15 | 焦顺昌 | 一种靶向kras突变的异体抗原递呈细胞、构建方法及肠癌特异性ctl细胞的制备方法 |
| CN110184238A (zh) * | 2019-06-11 | 2019-08-30 | 北京鼎成肽源生物技术有限公司 | 一种靶向kras多发突变肿瘤的特异性ctl细胞的制备方法及应用 |
| CN114651001A (zh) * | 2019-11-07 | 2022-06-21 | 武汉华大吉诺因生物科技有限公司 | 肿瘤免疫治疗多肽及其应用 |
| EP4293043A1 (en) * | 2021-02-10 | 2023-12-20 | Shanghai Genbase Biotechnology Co., Ltd. | Epitope peptide of ras g13d mutant and t cell receptor recognizing ras g13d mutant |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2328689A (en) * | 1997-08-27 | 1999-03-03 | Norsk Hydro As | Peptides based on the p21 ras proto-oncogene protein for the treatment of cancer |
| NO309798B1 (no) * | 1999-04-30 | 2001-04-02 | Targovax As | Peptidblanding, samt farmasoytisk sammensetning og kreftvaksine som innbefatter peptidblandingen |
| EP1762575A1 (en) * | 2005-09-12 | 2007-03-14 | Ganymed Pharmaceuticals AG | Identification of tumor-associated antigens for diagnosis and therapy |
| TW200806789A (en) * | 2006-03-27 | 2008-02-01 | Globeimmune Inc | RAS mutation and compositions and methods related thereto |
-
2016
- 2016-06-16 BR BR112017025728A patent/BR112017025728A2/pt not_active Application Discontinuation
- 2016-06-16 CN CN201680035219.2A patent/CN107922472A/zh active Pending
- 2016-06-16 RU RU2018101225A patent/RU2018101225A/ru not_active Application Discontinuation
- 2016-06-16 AU AU2016280770A patent/AU2016280770A1/en not_active Abandoned
- 2016-06-16 KR KR1020187001072A patent/KR20180021072A/ko unknown
- 2016-06-16 MX MX2017015927A patent/MX2017015927A/es unknown
- 2016-06-16 WO PCT/EP2016/063920 patent/WO2016202937A1/en active Application Filing
- 2016-06-16 CA CA2989373A patent/CA2989373A1/en not_active Abandoned
- 2016-06-16 JP JP2017564742A patent/JP2018518177A/ja active Pending
- 2016-06-16 EP EP16736394.4A patent/EP3310808A1/en not_active Withdrawn
- 2016-06-16 US US15/736,472 patent/US20190374628A1/en not_active Abandoned
-
2017
- 2017-12-04 IL IL256077A patent/IL256077A/en unknown
- 2017-12-15 CL CL2017003228A patent/CL2017003228A1/es unknown
-
2018
- 2018-06-14 HK HK18107744.4A patent/HK1248714A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2016280770A1 (en) | 2018-01-04 |
| MX2017015927A (es) | 2018-04-18 |
| CA2989373A1 (en) | 2016-12-22 |
| US20190374628A1 (en) | 2019-12-12 |
| JP2018518177A (ja) | 2018-07-12 |
| CN107922472A (zh) | 2018-04-17 |
| RU2018101225A (ru) | 2019-07-16 |
| KR20180021072A (ko) | 2018-02-28 |
| WO2016202937A1 (en) | 2016-12-22 |
| HK1248714A1 (zh) | 2018-10-19 |
| EP3310808A1 (en) | 2018-04-25 |
| IL256077A (en) | 2018-01-31 |
| CL2017003228A1 (es) | 2018-07-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112017025728A2 (pt) | fragmentos mutantes da proteína ras | |
| BR112016013138A2 (pt) | mistura de peptídeos | |
| CL2021000343A1 (es) | Inhibidores peptídicos del receptor de interleucina 23 (divisional de la solicitud n° 201800128) | |
| CL2020001852A1 (es) | Procesos de preparación de s-ketamina o clorhidrato de s-ketamina o productos derivados de éste. (divisional solicitud 201901066) | |
| CY1121359T1 (el) | Ενωσεις ετεροαρυλιου για αναστολη κινασης | |
| BR112018010805A2 (pt) | mutantes de proteína f de rsv | |
| BR112018074700A2 (pt) | variantes de protease e usos das mesmas | |
| CL2018002826A1 (es) | Proteínas f de prefusión del virus respiratorio sincicial (vrs) solubles y estabilizadas | |
| BR112017019170A2 (pt) | métodos para o tratamento de doença do fígado gorduroso não alcoólico e / ou lipodistrofia | |
| BR112017008962A2 (pt) | proteínas de fusão inibidoras de c1 esterase e usos das mesmas | |
| BR112018076215A2 (pt) | partículas e composições de nicotina | |
| BR112017003472A2 (pt) | anticorpos, fragmento fab de anticorpo e método para o tratamento de uma doença inflamatória | |
| BR112018071107A2 (pt) | composições e métodos para a detecção de proteínas da célula hospedeira | |
| BR112017020308A2 (pt) | udp-glicosiltransferases | |
| BR112016026842A2 (pt) | preparação compreendendo fator viii e peptídeos de fator de von willebrand | |
| BR112019003785A2 (pt) | tabaco resistente a vírus e método de melhoramento para o mesmo | |
| BR112021025438A2 (pt) | Composições de proteínas anti-vegf e métodos para produzir as mesmas | |
| BR112018012304A2 (pt) | composições e métodos para diminuir expressão de tau | |
| BR112017018703A2 (pt) | peptídeo derivado de gpc3, composição farmacêutica para tratamento ou prevenção de câncer usando o mesmo, indutor de imunidade, e método para produzir células de apresentação de antígeno | |
| BR112018010160A2 (pt) | inibidor da c1 esterase humana recombinante e usos do mesmo | |
| BR112017017609A2 (pt) | proteína de fusão fc, e, composição farmacêutica. | |
| BR112017022208A2 (pt) | sistema espinhal poliaxial expansível | |
| BR112015023886A2 (pt) | polipeptídeo, ácido nucleico, composição farmacêutica, e, método | |
| BR112018008840A2 (pt) | anticorpos de domínio único direcionados contra antígenos intracelulares | |
| MY190102A (en) | Tolerogenic dna vaccine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |